{"id":"31011a4b-1d17-5615-ab80-b4949d94e986","stable_key":"182336c6-ed36-5ec6-8a09-25c31096262e:dim-duloxetine-inhibition","predicate":"increases","statement":"Fluvoxamine increased oral duloxetine AUC by 460% and peak concentration by 141% in the clinical study.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"07419d34-4ddc-5a8c-a145-9a621ed5d18c","mechanism_event_label":"Blocking metabolism increased exposure; this measured result must not be relabeled as a DIM study.","subject":{"id":"df26c2cc-f2ee-543e-81ce-7a332fe3b644","slug":"fluvoxamine","display_name":"Fluvoxamine","entity_type_key":"small_molecule"},"object":{"id":"d38a8ca3-7971-52d5-ba53-b0de7e502f23","slug":"duloxetine-plasma-exposure","display_name":"Plasma duloxetine exposure","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"07419d34-4ddc-5a8c-a145-9a621ed5d18c","stable_key":"182336c6-ed36-5ec6-8a09-25c31096262e:dim-duloxetine-inhibition-event","event_type":"observed_intervention","label":"Blocking metabolism increased exposure; this measured result must not be relabeled as a DIM study.","description":"Fluvoxamine increased oral duloxetine AUC by 460% and peak concentration by 141% in the clinical study.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"77ccdbfd-eff7-5b34-930f-af7664c36b77","slug":"duloxetine","display_name":"Duloxetine","entity_type_key":"small_molecule"},"role":"measured_drug","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"9b15c13c-a369-5d10-a76a-525e8b19221d","slug":"cyp1a2","display_name":"Human cytochrome P450 1A2","entity_type_key":"protein"},"role":"inhibited_pathway","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"df26c2cc-f2ee-543e-81ce-7a332fe3b644","slug":"fluvoxamine","display_name":"Fluvoxamine","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"d38a8ca3-7971-52d5-ba53-b0de7e502f23","slug":"duloxetine-plasma-exposure","display_name":"Plasma duloxetine exposure","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/dim-research/18307373.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"2705ee887855e9dbe738ece57d4ad9d4b3d8cc0d67de45e63c01497a4a215149\", \"start_char\": 0, \"end_char\": 2879, \"text_sha256\": \"2705ee887855e9dbe738ece57d4ad9d4b3d8cc0d67de45e63c01497a4a215149\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Enzyme phenotyping and clinical drug-interaction studies","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Fluvoxamine with oral or intravenous duloxetine","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"The clinical exposure change was caused by fluvoxamine, not DIM. The study tests inhibition, not the inverse size of induction.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Diindolylmethane (DIM) research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"dim","display_name":"3,3'-Diindolylmethane / DIM","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Human enzyme systems and healthy adults","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Blocking metabolism increased exposure; this measured result must not be relabeled as a DIM study.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[dim-p18307373] In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. (2008). https://pubmed.ncbi.nlm.nih.gov/18307373/ DOI: 10.2165/00003088-200847030-00005","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Duloxetine metabolism and exposure","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"8cc5009b-a1ed-519f-88e5-c8a33010fcd0","evidence_kind":"source_excerpt","locator":"Lines 805-816","start_line":805,"end_line":816,"excerpt":"### dim-duloxetine-inhibition\nFluvoxamine increased oral duloxetine AUC by 460% and peak concentration by 141% in the clinical study.\nCondition category: normal\nnutrient_topic: Diindolylmethane (DIM) research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: Blocking metabolism increased exposure; this measured result must not be relabeled as a DIM study.\norganism: Human enzyme systems and healthy adults\ntissue_or_cell_type: Duloxetine metabolism and exposure\nexperimental_model: Enzyme phenotyping and clinical drug-interaction studies\nlimitations: The clinical exposure change was caused by fluvoxamine, not DIM. The study tests inhibition, not the inverse size of induction.\nexposure: Fluvoxamine with oral or intravenous duloxetine\nevidence_span: {\"source_cache\": \"artifacts/dim-research/18307373.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"2705ee887855e9dbe738ece57d4ad9d4b3d8cc0d67de45e63c01497a4a215149\", \"start_char\": 0, \"end_char\": 2879, \"text_sha256\": \"2705ee887855e9dbe738ece57d4ad9d4b3d8cc0d67de45e63c01497a4a215149\"}\n[dim-p18307373] In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. (2008). https://pubmed.ncbi.nlm.nih.gov/18307373/ DOI: 10.2165/00003088-200847030-00005","model_system":"Enzyme phenotyping and clinical drug-interaction studies","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [dim-p18307373] In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. (2008). https://pubmed.ncbi.nlm.nih.gov/18307373/ DOI: 10.2165/00003088-200847030-00005","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"b6d70682-97f9-5893-a03c-f9f88836033c","stable_key":"import-182336c6-ed36-5ec6-8a09-25c31096262e","title":"Diindolylmethane (DIM): formation, receptor signaling, metabolism and drug interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"31e14060de904976d2f5d439f2bc9c8a99a72d34626c562c78429025e050d404","revision_id":"611094c1-a9cf-5b9b-b255-ac70b571696a","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}